The Emerging Role of HLA-E-Restricted CD8⁺ T Lymphocytes in the Adaptive Immune Response to Pathogens and Tumors

Table 1

Both the HLA class I host haplotype and the infecting CMV strain can affect the ability of different individuals to exploit an HLA-E-restricted CD8⁺ T-cell-mediated defence against CMV.

Donors	HLA-Cw haplotype	HLA-A haplotype	VMAPRTLIL^1	VMAPRTLVL^2	HLA-E restricted CD8^+ T cells against CMV
Group 1	HLA-Cw*02, -Cw*07, -Cw*0809, -Cw*15, -Cw*1701, Cw*1703, and -Cw*18^3	HLA-A*01, -A*03, -A*11, -A*29, -A*30, -A*33, -A*3401, -A*36, -A*74, and -A*80^4	nonself peptide	nonself peptide	YES (against both AD169 and Toledo strains)
Group 2	HLA-Cw*02, -Cw*07, -Cw*0809, -Cw*15, -Cw*1701, Cw*1703, and -Cw*18^3	HLA-A*02, -A*23, -A*24, -A*25, -A*26, -A*3402, -A*43, -A*66, and -A*69^5	nonself peptide	self peptide	YES (against AD169 strain but not against Toledo strain)

1This peptide is contained in the UL40 open reading frame (ORF) from human CMV AD169 strain.
2This peptide is contained in the UL40 ORF from human CMV Toledo strain.
3These HLA-*CW alleles do not contain in their leader sequences the VMAPRTLIL peptide.
4These HLA-*A alleles do not contain in their leader sequences the VMAPRTLVL peptide.
5These HLA-*A alleles do contain in their leader sequences the VMAPRTLVL peptide.